March 11, 2011 08:32 ET

Equity Research on Elan Corp. plc and Valeant Pharmaceuticals International - Drug Delivery Sector Sees Opportunities and Growing Sales

NEW YORK, NY--(Marketwire - March 11, 2011) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the drug delivery industry and are offering free analytical research on Elan Corp. plc (NYSE: ELN) and Valeant Pharmaceuticals International (NYSE: VRX). Register with us today at to have free access to this research and speak to one of our pros.

There are several broad trends that are making the Drug Delivery sector attractive these days. One is the advent of new biotechnologies and gene-based therapies. These intrinsically difficult to administer treatments represent a major growth opportunity for companies within the Drug Delivery Sector. Also, the coming patent cliff offers a unique opportunity for companies within the sector to develop improved delivery systems for several drugs coming to the generics market, and help them garner market share. Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future. is the Ultimate Trading Environment for investors. If you are considering owning Elan Corp. plc and Valeant Pharmaceuticals International then you should sign up for a free membership and our complimentary reports today at Over the last 5 years our returns outpaced any of the major indexes. Shine's performance in 2005 was +14%, 2006 + 26%, 2007 +99%, 2008 + 355% and 2009 + 46%. Sign up today to find out what you are missing. 

More specifically, a piece of good news for the sector has been the European approval of a new diagnostic test for Tysabri to determine if patients are prone to its potentially severely harmful side effects. This test should help mitigate some of the tepid growth the drug had been experiencing due to cautious doctor sentiments. Tysabri, which is sold in part by Elan Corp. plc saw its sales grow to $1.2 billion last year. Elan Corp. plc report is accessible for free by registering today at

Elsewhere in the neurology space, Valeant Pharmaceuticals International has been strong. While it posted a Q4 loss due in part to restructuring costs, sales in its neurology segment grew 32%. Valeant Pharmaceuticals International report is accessible for free by registering today at

The two drug delivery stocks research reports are available for free by signing up now on


Shine's Room Online is the brain child of David Shine, a 15 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

Contact Information